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The elegant Sanger sequencing technique, however, was no exception to unrelenting technological advances, and soon it was all but replaced by the technique of massively parallel nucleic acid sequencing, which is often referred to as next generation sequencing. 12 The new technology made sequencing of the entire human genome, which was unfathomable a few years earlier, with the exception of large-scale efforts, such as the Human Genome Project, a reality. Similarly, advances in the DNA capture technology made it possible to capture and enrich the coding regions of the genome, where the vast majority of the discovered mutations for monogenic diseases reside. Technological advances also led to a precipitous drop in the cost of nucleic acid sequencing. The drop is often compared with the Moore law on the transistor packing capacity in computing. These advances along with the assenting recommendations from the professional societies propelled routine genetic testing to the daily practice of cardiovascular medicine.
Application of the massively parallel sequencing technology to genetic testing at the clinic, however, exposed even bigger challenges of how to interpret the findings and apply them to the care of the individual. The primary challenge has been identifying the causal variant(s) among 4 million or so variants in each genome, including >12 000 nonsynonymous, and several hundred if not thousand putatively functional and pathogenic variants. 13, 14 The plethora of the variants in each genome is inherent to the rare error rate of DNA replication machinery, which is estimated as well as empirically shown to be at 1×10 −8 per base. 15, 16 Accordingly, ≈ 30 de novo variants are generated with each meiosis. The challenge is further amplified by the enormous genetic diversity of the humans, which is reflective of the explosive growth of the human population during the past 1000 years or so, as with each birth ≈ 30 new variants are introduced to the population pool. 17 Consequently, in a given population rare variants, defined as variants with a minor allele frequency of <0.01, are more common than the common variants. Empirical data indeed show that ≈86% of the variants in a given population have a minor allele frequency of ≤0.5%. 18 Moreover, 96% of putative functional variants in the population are rare variants. 18 Because of such complexity, the majority of the genetic testing laboratories are focused on analysis of the rare variants in genes previously identified to be causal in the phenotype of interest. A commonly used approach is whole exome sequencing (WES) followed by post hoc analysis restricted to the known genes. An alternative approach is to capture and sequence, using a massively parallel sequencing platform, and analyze the protein-coding exons in the candidate genes. Regardless of the approach, the goal is to identify the putatively pathogenic variants, defined as rare nonsense, missense, splicing, and insertion/deletion variants and establish their causal role in the disease.
The group led by Joe Wu at Stanford University have applied a recently described target DNA capture technique to screen patients with hereditary cardiomyopathies for detection of the pathogenic variants in 88 candidate genes and 40 miRNAs. 19 The authors use a DNA capture technique referred
Marian

Genetic Testing 587
to as complementary long padock probes (cLPPs). 20 The assay uses long double-stranded oligonucleotide probes, as opposed to the conventional single-stranded probes, for hybridization to the intended genomic targets (typically exons). Hybridization is followed by circularization through end ligation, capture, polymerase chain reaction amplification of the captured target, and sequencing using a massively parallel sequencing platform. Because both strands of the target DNA are captured independently, the assay is expected to increase sensitivity and specificity of variant detection. 20 The authors screened 19 individuals with cardiomyopathies, 10 clinically unaffected family members, and 6 HapMap samples using the cLPPS method. The study was designed to test performance metrics of the assay as well as detect variants in the candidate miRNAs in patients with cardiomyopathies. The authors sequenced ≈1.15 million bases of DNA per each individual. The base coverage was excellent because 97% of the bases were sequenced at least 20×, which is more than sufficient for an accurate variant calling. The cLPPs assay correctly identified the presence or absence of the known variants in all 35 cases, whether affected or phenotypically normal individuals or the HapMap samples. Performance metrics of the cLPPs method was compared against WES data in 12 exomes. Notably, cLPPs missed 3.8% of protein-coding variants as opposed to 17.1% by the WES approach, assuming that all variants identified by either technique were valid and not artifacts. No notable pathogenic variant in the miRNAs were identified, which would be in accord with the biological functions of miRNAs as genomic nudgers and tweaker. 21 The main strength of the cLPPs method relates to its fundamental principle of capturing and sequencing both strands of DNA as opposed to one of the strands. Therefore, inherent to the assay is the potential for a higher sensitivity and specificity for variant detection. The data presented by Wilson et al 19 support this notion, albeit the data on the performance metrics of the assay are based on a small number of samples. As indicated by the authors, the findings would require further validation in larger sample size study populations. Likewise, the capture technique would requires further refinement in the design of capture probes and capture conditions to enhance efficiency, particularly for the GC-rich regions. Nevertheless, given that the capture efficiency in WES approach is remarkably high and the detection rate of the known mutations is >90% (different than the yield of de novo genetic testing), further enhancement of the cLPPs method would advance mutation detection rate to near perfection. The cLPPs method also seems to be less time consuming and somewhat cheaper, albeit the cost calculations are restricted only to the cost of the assay and do not include additional costs related to operation of the sequencing instruments, bioinformatics, or the personnel. Considering the above, the cLLPs technique, on further validation and refinement, would be expected to offer advantages during the existing capture-based candidate gene approaches.
The candidate gene approach, regardless of the method used, has many limitations. First and foremost, approximately one third of the causal genes for monogenic cardiovascular diseases, including hereditary cardiomyopathies, remain to be identified. Therefore, the candidate gene approach is not suited for novel discoveries, which is an important component of the research programs in major genetic laboratories. Second, the detected variants, despite residing in the candidate gene(s), often are novel, hence, not linked to the phenotype of interest, and have no clear biological functions. Third, with the increasing availability of large data sets of genetic variants, such as the Exome Aggregation Consortium data set (http:// exac.broadinstitute.org/), some of the previously categorized causal variants could be re-categorized as rare or uncommon variants with unsettled pathogenic role in the phenotype of interest. Fourth, in silico algorithms are helpful but not robust in predicting pathogenicity of the variants. Finally, the financial cost, when not covered by the third party payers, could become a hindrance. Consequently, genetic testing based on the candidate gene approach, when fails to identify the causal variant(s), disappoints the physicians and the patients alike. The cLLPs method by improving sensitivity and specificity of the detection, on further refinement and validation, could assuage some of the above concerns.
Technological advances such as the method described by Wilson et al 19 could further shift the focus in genetic testing from variant detection to interpretation of the findings and their applications at the bedside. Considering that every genome or exome has several thousand potentially damaging variants, a couple of hundred heterozygous loss-of-function variants, and a couple of dozens stop codon variants, [22] [23] [24] detection of a pathogenic variant in a single genome or exome does not portend unambiguous evidence for the causal role of the variant in the disease of interest. Consequently, the emphasis is to characterize as many family members as possible, as the main strength of the genetic testing is in the family setting, which offers the opportunity to analyze cosegregation of the variants with inheritance of the disease. In accord with this viewpoint, cascade screening of the family members at risk is strongly encouraged by various professional societies. However, it is equally important to remain caution in interpretation of cosegregation data in small size families, as such could also occur by chance alone.
Establishing causality for genetic variants is usually a matter of statistical probability, as seldom the Koch postulates of causality are totally fulfilled. 25 The probability partly depends on the effect size of the variants, which in the population follows a gradient ranging from negligible to large. 26 Few variants in the genome exhibit large effect sizes, and therefore, are highly penetrant, and perfectly cosegregate with inheritance of the phenotype. A causal role for such variants could be ascertained with reasonable certainty in large families. Likewise, genetic testing is most fruitful for the highly penetrant variants and through cascade testing in the family members. Unfortunately, however, such variants encompass only a minority of the cases, as often the family size is too small, or the disease is sporadic, or the variant(s) is not highly penetrant. In such scenarios, and given the presence of a large number of putatively damaging variants in each genome/exome, establishing causality is challenging and so is the clinical use of genetic testing. Often strong statistical evidence through population studies or biological data through experimentation or both are required to infer a possible causal role and to guide interpretation of the genetic testing data.
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In view of the increasing use of genetic testing in clinical practice, National Institutes of Health and professional health organizations have emphasized the need for improving genomic literacy of physicians and other healthcare providers. 27 Genetic testing is occasionally straightforward and could be implemented by educated clinicians and geneticists. Unfortunately, in view of the complexity of the genome, phenotypic variability of the disease, and plasticity of the ensuing phenotype, as well as multiplicity of the pathogenic determinants of the phenotype, interpretation of the genetic findings is best left to those who have specific training and expertise in this area. Often Sherlock Holmes type of investigative approach is necessary to properly apply the genetic findings at the bedside. Furthermore, to advance the field beyond the knowns, the focus of the major genetic laboratories has to be on identification and annotation of all pathogenic variants in the exome by WES and preferably in the genome, followed by developing integrative approaches to incorporate data from biological experiments, population genetics, and most importantly, the specific phenotypic characteristics of the individual at risk or with expressed disease. As such, genetic testing results have to be tailored to an individual. It is this deep appreciation for the unique genetic and phenotypic characteristics of an individual that is elegantly depicted by Sir William Osler famous quote: The good physician treats the disease; the great physician treats the patient who has the disease.
